Cannabis had a breakout year in 2016, and the inclusion of 4 cannabis companies in 2017 TSX Venture Top 50 clearly shows that there is a lot more to look forward to from this sector.
Companies across different sectors were evaluated via a ranking method that looked at 1,643 companies’ share price, trading volume and market capitalization.
Here is a look at the four cannabis companies that made it into the 2017 TSX Venture Top 50:

Aphria (TSXV:APH)

Aphria is a producer and supplier of medical cannabis in Ontario. In February, the company announced approval to graduate from the TSX Venture Exchange to the TSX, and is set to be finalized on or before May 3, 2017. Upon completion of the final listing requirements, Aphria’s shares will be delisted from the TSX Venture Exchange and will commence trading on the TSX.
Over a one-year period, the company’s share price has gained 457.14 percent.

Emerald Health Therapeutics (TSXV:EMH)

Emerald Health Therapeutics is a company focused on cultivating and selling medical cannabis through the Marihuana for Medical Purposes Regulations (MMPR). The company operates a cultivation facility in Victoria, British Columbia, and is planning to construct a 32 acre hybrid greenhouse facility in metro Vancouver. Emerald sells cannabis-based oils and dried cannabis.
Over a one-year period, the Emerald Health Therapeutics share price has gained 645.45 percent.

OrganiGram Holding (TSXV:OGI)

OrganiGram prides itself in growing organic medical marijuana, licensed under MMPR, and with a production facility in New Brunswick. The company recently found itself facing a proposed class-action lawsuit filed by a Halifax-based firm representing Organigram clients who claim they purchased and consumed their product and found it to contain trace elements of pesticides. In response, the company said it plans to “vigorously defend our company and its actions related to the product recall.” The class-action lawsuit only contains allegations that are not yet tested in court as of March 8, 2017.
Over a one-year period, the company’s share price has gone up by 174.36 percent.

Mettrum Health

Mettrum was acquired by Canopy Growth (TSX:CGC) in December 2016. Canopy Growth operates various brands in marijuana-related companies. The arrangement is anticipated to be completed soon.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Pia Rivera, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Mettrum is a client of the Investing News Network. This article is not paid-for content.

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email or for information on the class action.

Keep reading... Show less